Clinical Trial

Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment

Study acronym: DeLLphi-307
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary aim of this study is to evaluate the efficacy of tarlatamab as assessed by objective response rate (ORR) based on blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).
Protocol Amendment History 1 change
minor Completion pushed: 2027-01-08 -> 2027-09-10 2026-07-10
Trial Details
NCT Number NCT06502977
Lead Sponsor Amgen
Conditions Extensive Stage Small Cell Lung Cancer
Enrollment 32 participants
Start Date 2024-08-27
Primary Completion 2025-03-28 (estimated)
Study Completion 2027-09-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-09